biostudies-literatureUnknown14(12)Goosen TCIsavuconazole is a broad-spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co-administration of isavuconazole with anticancer drugs-limited by the availability of clinical drug-drug interaction (DDI) data in the patient population. This study utilized physiologically-based pharmacokinetic (PBPK) modeling to evaluate the DDI risk of isavuconazole compared with other azoles and provide dosing recommendations when co-administered with anticancer drugs (ibrutinib, venetoclax, and midostaurin). PBPK models were developed in the Simcyp simulator using physiochemical properties, in vitro, and clinical pharmacokinetic data. The model well-predicted isavuconazole pCPT: pharmacometrics & systems pharmacology2198-2209https://www.ebi.ac.uk/biostudies/studies/S-EPMC12706401biostudies-literatureComparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model-Informed Dosing Recommendations for Anticancer Drugs.PMC12706401Raber SRCheruvu NVarma MVSGoosen TCLin Jde Figueiredo MLNWu XfalseComparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model-Informed Dosing Recommendations for Anticancer Drugs.Isavuconazole is a broad-spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co-administration of isavuconazole with anticancer drugs-limited by the availability of clinical drug-drug interaction (DDI) data in the patient population. This study utilized physiologically-based pharmacokinetic (PBPK) modeling to evaluate the DDI risk of isavuconazole compared with other azoles and provide dosing recommendations when co-administered with anticancer drugs (ibrutinib, venetoclax, and midostaurin). PBPK models were developed in the Simcyp simulator using physiochemical properties, in vitro, and clinical pharmacokinetic data. The model well-predicted isavuconazole p2025-01-01T00:00:00Z2025 Dec2026-06-07T05:04:54.254Z2026-06-07T03:06:55.281ZS-EPMC127064014110461110.1002/psp4.70123